Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.

Clinical Journal of Pain

Volumn 31, Issue 1, 2015, Pages 21-29

  Orrey, Danielle C ^a   Halawa, Omar I ^a   Bortsov, Andrey V ^a   Shupp, Jeffrey W ^c   Jones, Samuel W ^a   Haith, Linwood R ^d   Hoskins, Janelle M ^a   Jordan, Marion H ^c   Bangdiwala, Shrikant I ^a   Roane, Brandon R ^a   Platts Mills, Timothy F ^a   Holmes, James H ^b   Hwang, James ^a   Cairns, Bruce A ^a   McLean, Samuel A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d CROZER CHESTER MEDICAL CENTER   (United States)

Author keywords

burn; catechol O methyltransferase; propranolol; randomized control trial

Indexed keywords

CATECHOL METHYLTRANSFERASE; PROPRANOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COMT PROTEIN, HUMAN;

ADULT; ARTICLE; BLEEDING; BURN; BURN PATIENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEART ARRHYTHMIA; HEPATOBILIARY DISEASE; HOMOZYGOTE; HOSPITAL ADMISSION; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLIC DISORDER; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PAIN SEVERITY; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SKIN TOXICITY; TREATMENT OUTCOME; BURN UNIT; BURNS; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; GENETICS; MULTICENTER STUDY; PAIN MEASUREMENT; PATIENT COMPLIANCE; PSYCHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TIME FACTOR; YOUNG ADULT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BURN UNITS; BURNS; CATECHOL O-METHYLTRANSFERASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; PAIN; PAIN MEASUREMENT; PATIENT COMPLIANCE; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPRANOLOL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84918840079     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0000000000000086     Document Type: Article

References (54)

1. LaBorde P. Burn epidemiology: the patient, the nation, the statistics, and the data resources. Crit Care Nurs Clin North Am. 2004;16:13-25.
2. Gallagher G, Rae CP, Kinsella J. Treatment of pain in severe burns. Am J Clin Dermatol. 2000;1:329-335.
3. Perry S, Heidrich G, Ramos E. Assessment of pain by burn patients. J Burn Care Res. 1981;2:322-326.
4. Summer GJ, Puntillo KA, Miaskowski C, et al. Burn injury pain: the continuing challenge. J Pain. 2007;8:533-548.
5. Khasar SG, Green PG, Miao FJ, et al. Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat. Eur J Neurosci. 2003;17:909-915.
6. Khasar SG, McCarter G, Levine JD. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol. 1999;81:1104-1112.
7. Nackley AG, Tan KS, Fecho K, et al. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both b2- and b3-adrenergic receptors. Pain. 2007;128: 199-208.
8. Kaplan R, Robinson CA, Scavulli JF, et al. Propranolol and the treatment of rheumatoid arthritis. Arthritis Rheum. 1980; 23:253-255.
9. Hocking LJ, Smith BH, Jones GT, et al. Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: results from the 1958 British Birth Cohort Study. Pain. 2010;149:143-151.
10. Diatchenko L, Anderson AD, Slade GD, et al. Three major haplotypes of the b2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet. 2006;141B:449-462.
11. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, et al. Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum. 2009;60:2169-2173.
12. Tchivileva IE, Lim PF, Smith SB, et al. Effect of catechol-Omethyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, doubleblind, placebo-controlled, crossover pilot study. Pharmacogenet Genom. 2010;20:239-248.
13. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51:593-628.
14. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135-143.
15. Rosen JA. Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann Neurol. 1983;13:92-93.
16. Diamond S, Kudrow L, Stevens J, et al. Long-term study of propranolol in the treatment of migraine. Headache. 1982;22: 268-271.
17. Murray TJ. Long-term therapy of essential tremor with propranolol. Can Med Assoc J. 1976;115:892-894.
18. Sweet RD, Blumberg J, Lee JE, et al. Propranolol treatment of essential tremor. Neurology. 1974;24:64-67.
19. Winkler GF, Young RR. Efficacy of chronic propranolol therapy in action tremors of the familial, senile or essential varieties. N Engl J Med. 1974;290:984-988.
20. Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp. 2007;280:238-248; discussion 248-251.
21. Pereira CT, Herndon DN. The pharmacologic modulation of the hypermetabolic response to burns. Adv Surg. 2005;39: 245-261.
22. Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet. 2004;363:1895-1902.
23. Eldon MA, Kinkel AW, Daniel JE, et al. Bioavailability of propranolol hydrochloride tablet formulations: application of multiple dose crossover studies. Biopharm Drug Dispos. 1989; 10:69-76.
24. Aardex Group. Available at: http://www.aardexgroup.com/ aardex-index.php?group=aardex. Accessed March 5, 2012.
25. Nuesch R, Schroeder K, Dieterle T, et al. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ. 2001;323:142-146.
26. Brunet A, Weiss D, Metzler T, et al. The peritraumatic distress inventory: a proposed measure of PTSD criterion A2. Am J Psychiatry. 2001;158:1480-1485.
27. Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med. 2003;10: 390-392.
28. Foa EB, Tolin DF. Comparison of the PTSD symptom scaleinterview version and the clinician-administered PTSD scale. J Trauma Stress. 2000;13:181-191.
29. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
30. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002;51:189-192.
31. Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003;54:947-949.
32. Taylor F, Cahill L. Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. J Trauma Stress. 2002;15:433-437.
33. Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, Acute Type A Pilot Study. Arch Pediatr Adolesc Med. 1988;142:1244-1247.
34. McGhee LL, Maani CV, Garza TH, et al. The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res. 2009;30:92-97.
35. Stein MB, Kerridge C, Dimsdale JE, et al. Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-ofconcept trial in physically injured patients. J Trauma Stress. 2007;20:923-932.
36. Foa EB, Riggs DS, Dancu CV, et al. Reliability and validity of a brief instrument for assessing posttraumatic stress disorder. J Trauma Stress. 1993;6:459-473.
37. Shyong EQ, Lucchinetti E, Tagliente TM, et al. Interleukin balance and early recovery from anesthesia in elderly surgical patients exposed to beta-adrenergic antagonism. J Clin Anesth. 2003;15:170-178.
38. Zeger S, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
39. Eisen SA, Kang HK, Murphy FM, et al. Gulf War veterans health: medical evaluation of a US cohort. Ann Intern Med. 2005;142:881-890.
40. Parker C, Chen Z, Price M, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med. 2007;22:1254-1259.
41. Cramer J, Vachon L, Desforges C, et al. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia. 1995;36: 1111-1117.
42. Liang S-Y, Yates P, Edwards H, et al. Factors influencing opioidtaking self-efficacy and analgesic adherence in Taiwanese outpatients with cancer. Psychooncology. 2008;17:1100-1107.
43. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
44. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29:S2-S10.
45. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol. 2002;109:S554-S559.
46. World Health Organization. Adherence to long-term therapies-evidence for action 2003. Available at: http://apps. who.int/medicinedocs/pdf/s4883e/s4883e.pdf. Accessed March 8, 2012.
47. Vlasnik JJ, Aliotta SL, DeLor B. Medication adherence: factors influencing compliance with prescribed medication plans. Case Manager. 2005;16:47-51.
48. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010; 63.8:e1-e37.
49. Tolstoy L. Anna Karenin. Vol. 1. Collier; 1917.
50. Choinier M, Melzack R, Rondeau J, et al. The pain of burns: characteristics and correlates. J Trauma Acute Care Surg. 1989;29:1531-1539.
51. Scadding JW, Wall PD, Wynn Parry CB, et al. Clinical trial of propranolol in post-traumatic neuralgia. Pain. 1982;14:283-292.
52. Tchivileva IE, Lim PF, Kasravi P, et al. Propranolol in Temporomandibular Joint Disorder Treatment. San Diego, CA: American Pain Society; 2009.
53. Orrey DC, Bortsov AV, Hoskins JM, et al. Catechol-Omethyltransferase genotype predicts pain severity in hospitalized burn patients. J Burn Care Res. 2012;33:518-523.
54. National Burn Repository 2011 Report; 2011. Available at: http://www.ameriburn.org/2011NBRAnnualReport.pdf. Accessed March 8, 2012.